Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Purpose: Sensitize melanomas to apoptosis and inhibit their growth and metastatic potential by compounds that mimic the activities of activating transcription factor 2 (ATF2)-driven peptides. Experimental Design: Small-molecule chemical library consisting of 3,280 compounds was screened to identify compounds that elicit properties identified for ATF2 peptide, including (a) sensitization of melanoma cells to apoptosis, (b) inhibition of ATF2 transcriptional activity, (c) activation of c-Jun NH2-terminal kinase (JNK) and c-Jun transcriptional activity, and (d) inhibition of melanoma growth and metastasis in mouse models. Results: Two compounds, celastrol (CSL) and acetyl isogambogic acid, could, within a low micromolar range, efficiently elicit cell death in melanoma cells. Both compounds efficiently inhibit ATF2 transcriptional activities, activate JNK, and increase c-Jun transcriptional activities. Similar to the ATF2 peptide, both compounds require JNK activity for their ability to inhibit melanoma cell viability. Derivatives of CSL were identified as potent inducers of cell death in mouse and human melanomas. CSL and a derivative (CA19) could also efficiently inhibit growth of human and mouse melanoma tumors and reduce the number of lung metastases in syngeneic and xenograft mouse models. Conclusions: These studies show for the first time the effect of CSL and acetyl isogambogic acid on melanoma. These compounds elicit activities that resemble the well-characterized ATF2 peptide and may therefore offer new approaches for the treatment of this tumor type.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
MITF: master regulator of melanocyte development and melanoma oncogene
Levy, C., Khaled, M., & Fisher, D. E. (2006) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.07.008 · Cited by 1,169
Inhibition of JNK activation through NF-κB target genes
Tang, G., Minemoto, Y., Dibling, B., Purcell, N. H., Li, Z., Karin, M., & Lin, A. (2001) · Nature · doi:10.1038/35104568 · Cited by 721
Cited by
Sirota, M., Dudley, J. T., Kim, J., Chiang, A. P., Morgan, A. A., Sweet-Cordero, A., Sage, J., & Butte, A. J. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001318 · Cited by 799
Triterpenoids as new promising anticancer drugs
Petronelli, A., Pannitteri, G., & Testa, U. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328330fd90 · Cited by 381
Emerging roles of ATF2 and the dynamic AP1 network in cancer
Lopez-Bergami, P., Lau, E., & Ronai, Z. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2681 · Cited by 350
Self-citationKannaiyan, R., Shanmugam, M. K., & Sethi, G. (2011) · Cancer Letters · doi:10.1016/j.canlet.2010.10.025 · Cited by 346
Celastrol in cancer therapy: Recent developments, challenges and prospects
Lim, H. Y., Ong, P. S., Wang, L., Goel, A., Ding, L., Li-Ann Wong, A., Ho, P. C.-L., Sethi, G., Xiang, X., & Goh, B. C. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.08.030 · Cited by 118
Metadata
- Authors
- Abbas, S., Bhoumik, A., Dahl, R., Vasile, S., Krajewski, S., Cosford, N. D. P., & Ronai, Z. A.
- Venue
- Clinical Cancer Research
- Published
- 2007-11-15
- Volume
- 13
- Issue
- 22
- Pages
- 6769-6778
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2052887239
- Cited by
- 95
- References
- 3
- FWCI
- 19.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-1536
- The paper
- Abbas, S., Bhoumik, A., Dahl, R., Vasile, S., Krajewski, S., Cosford, N. D. P., & Ronai, Z. A. (2007). Preclinical Studies of Celastrol and Acetyl Isogambogic Acid in Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-1536
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.